2023
Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study
Nally L, Sherr J, Tichy E, Weyman K, Urban A, Shabanova V, McCollum S, Steffen A, Tamborlane W, Van Name M. Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study. Diabetic Medicine 2023, 40: e15123. PMID: 37078999, PMCID: PMC10524154, DOI: 10.1111/dme.15123.Peer-Reviewed Original ResearchConceptsBasal insulin injectionsDiabetic ketoacidosisPercent of participantsBlood β-hydroxybutyrateInsulin injectionsBasal insulin dosesBasal insulin typeType 1 diabetesManagement of youthDegludec groupSignificant ketosisAcute complicationsBasal insulinInsulin dosesRisk of ketosisInjected insulinHigher hemoglobinInsulin administrationElevated hemoglobinInsulin typeKetone levelsHigh riskSchool nursesDegludecLarger sample size
2020
Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin
Alustiza M, Hernández-Illán E, Juárez M, Giner-Calabuig M, Mira C, Martínez-Roca A, Bujanda L, Rodríguez-Moranta F, Cubiella J, de-Castro L, Marín-Gabriel JC, Herreros-de-Tejada A, Fernández-Bañares F, Nicolás-Pérez D, Giménez P, Martínez-Cardona C, Francés R, Murcia O, Jover R. Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin. Clinical And Translational Gastroenterology 2020, 11: e00143. PMID: 32352715, PMCID: PMC7145049, DOI: 10.14309/ctg.0000000000000143.Peer-Reviewed Original ResearchConceptsC-reactive proteinMultiple colonic polypsCytokine serum levelsIL-17AIL-6IL-4IL-2Colonic polypsIL-23Serum levelsMultiple polypsHigh-sensitivity enzyme-linked immunosorbentSerum/bloodControl peopleEnzyme-linked immunosorbentLevels of glucoseCytokine levelsMost patientsNormal colonoscopyTh17 cellsBasal insulinIL-10Smoking habitsInflammatory cytokinesImmune response
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2DegludecReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2018
Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
SIEBEL S, PATEL N, GALDERISI A, CARRIA L, TAMBORLANE W, SHERR J. Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy. Diabetes 2018, 67 DOI: 10.2337/db18-117-lb.Peer-Reviewed Original ResearchPlasma glucoseSGLT2i useBHB levelsMedtronic MiniMedBoehringer Ingelheim GmbHSGLT2 inhibitor therapyInterruption studiesRapid-acting insulinType 1 diabetesRisk of DKABasal insulin infusionEli LillySuppression of ketogenesisCanagliflozin therapyRescue doseSGLT2i therapySGLT2i treatmentBasal insulinInhibitor therapySGLT2 inhibitorsT1D patientsAdjunctive agentsMetabolic decompensationInsulin infusionJanssen PharmaceuticalsDoes Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control?
LIPSKA K, PARKER M, MOFFET H, HUANG E, KARTER A. Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control? Diabetes 2018, 67 DOI: 10.2337/db18-1311-p.Peer-Reviewed Original ResearchNeutral protamine HagedornType 2 diabetesReal-world clinical practiceSevere hypoglycemiaGlycemic controlInsulin analoguesClinical practiceKaiser Permanente Northern CaliforniaDiabetes medication useInsulin analogue useBasal insulin analoguesClinical trial populationsType of insulinHealth plan coverageHazard ratioInsulin initiationNPH insulinPatient characteristicsBasal insulinHemoglobin A1cMedication useSulfonylurea treatmentTrial populationHypoglycemic eventsNocturnal hypoglycemia
2017
Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrate
2015
The past, present, and future of basal insulins
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes/Metabolism Research And Reviews 2015, 32: 478-496. PMID: 26509843, DOI: 10.1002/dmrr.2763.Peer-Reviewed Original ResearchConceptsInsulin glargine 100Basal insulinGlargine 100Glycemic controlUnits/mLNew insulin glargine 300Neutral protamine Hagedorn (NPH) insulinBasal insulin peglisproNew insulin productsSimilar glycemic controlGood glycemic controlInsulin glargine 300Type 2 diabetesDuration of actionInsulin delivery techniquesGlargine 300Insulin detemirInsulin therapyInsulin degludecNew insulinsPharmacodynamic profileInsulin secretionPharmacodynamic propertiesPrandial increaseFundamental therapy
2014
Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusion
2006
Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin
Tsalikian E, Kollman C, Tamborlane W, Beck R, Fiallo-Scharer R, Fox L, Janz K, Ruedy K, Wilson D, Xing D, Weinzimer S. Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin. Diabetes Care 2006, 29: 2200-2204. PMID: 17003293, PMCID: PMC1584283, DOI: 10.2337/dc06-0495.Peer-Reviewed Original ResearchConceptsType 1 diabetesBasal insulinExercise sessionsFrequency of hypoglycemiaPrevention of hypoglycemiaRisk of hyperglycemiaInsulin pump therapyTarget heart rateCompletion of exerciseBlood ketone levelsStructured exercise sessionsYears of agePump therapyStudy groupKetone levelsHeart rateHypoglycemiaDay 1Crossover designDay 2DiabetesInsulinChildren 8Diabetes researchObservation period
1998
Effect of epinephrine on muscle glycogenolysis and insulin-stimulated muscle glycogen synthesis in humans
Laurent D, Petersen K, Russell R, Cline G, Shulman G. Effect of epinephrine on muscle glycogenolysis and insulin-stimulated muscle glycogen synthesis in humans. American Journal Of Physiology 1998, 274: e130-e138. PMID: 9458758, DOI: 10.1152/ajpendo.1998.274.1.e130.Peer-Reviewed Original ResearchConceptsInsulin-stimulated muscle glycogen synthesisMuscle glycogen synthesisMuscle glycogenolysisEpinephrine infusionPhysiological increaseWhole-body glucose oxidationMuscle glycogen synthesis ratesPlasma epinephrine concentrationEuglycemic hyperinsulinemic clampGlucose infusion rateEffect of epinephrineGlycogen synthesisInsulin-stimulated glycogenesisBasal insulinControl subjectsPlasma glucoseEpinephrine concentrationsFree fatty acidsBasal valuesInfusion rateGlycogen synthesis rateMuscle glycogenEpinephrineGlycogenolysisMajor impairment
1994
Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. Journal Of Clinical Investigation 1994, 93: 1131-1139. PMID: 8132753, PMCID: PMC294058, DOI: 10.1172/jci117065.Peer-Reviewed Original ResearchConceptsRecombinant human insulin-like growth factorInsulin-like growth factorHuman insulin-like growth factorMiddle-aged subjectsC-peptideYoung subjectsBasal IGF-I levelsHealthy middle-aged subjectsGlucose uptakeGrowth factorAdverse metabolic changesFree fatty acid levelsIGF-I levelsRelative insulin deficiencyEuglycemic clamp studiesFat oxidation rateDose-response relationshipFatty acid levelsInsulin-induced stimulationMiddle-aged adultsBasal insulinInsulin deficiencyMetabolic effectsClamp studiesRhIGF
1978
Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs
Shulman G, Liljenquist J, Williams P, Lacy W, Cherrington A. Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs. Journal Of Clinical Investigation 1978, 62: 487-491. PMID: 670404, PMCID: PMC371787, DOI: 10.1172/jci109150.Peer-Reviewed Original ResearchConceptsNet hepatic glucose uptakeHepatic glucose productionHepatic glucose uptakeGlucagon secretionHepatic glucose storageBasal insulinGlucagon levelsGlucose storageNet hepatic glucose productionGlucose productionGlucose uptakeAbility of hyperglycemiaPancreatic hormone releasePlasma glucagon concentrationsPlasma glucagon levelsInduction of hyperglycemiaPlasma glucose levelsPlasma glucose concentrationHepatic glucose balanceIntraportal insulinGlucagon concentrationsConscious dogsSomatostatin inhibitionGlucagon infusionGlucose disposal
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply